Latest

Interactive Corporate Presentation

September 2026 corporate presentation. Retina focused company with THREE LATE-STAGE PROGRAMS built on the ABC Platform.

Interactive corporate profile. Covering the ABC platform and the Zenkuda, KSI-501 and KSI-101 clinical programs.

Enrollment complete in the first 300-patient cohort of Phase 3 PEAK (KSI-101, MESI). TOPLINE DATA expected DECEMBER 2026.

POSITIVE GLOW2 Phase 3 results: Zenkuda™ dosed every 6 months, 62.5% ≥2-step DRSS improvement vs 3.3% sham. BLA-READY profile.

Selected (0)

I'm IR Kodiak AI Bot. I can help you explore this content, like:

What would you like to know?